Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach
出版年份 2023 全文链接
标题
Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach
作者
关键词
-
出版物
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-10-15
DOI
10.1007/s00280-023-04598-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Prediction for Plasma Trough Concentration and Optimal Dosing of Imatinib under Multiple Clinical Situations Using Physiologically Based Pharmacokinetic Modeling
- (2023) Dongmei Gao et al. ACS Omega
- Efficacy and safety exposure–response analyses of entrectinib in patients with advanced or metastatic solid tumors
- (2022) Francois Mercier et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib
- (2022) Rafal Dziadziuszko et al. Molecular Oncology
- Alectinib versus crizotinib in ALK ‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
- (2022) Yurong Wang et al. Cancer Medicine
- Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment
- (2022) Lifang Xu et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients with hepatic/renal impairment
- (2022) Zhongjian Wang et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors
- (2021) Georgina Meneses-Lorente et al. INVESTIGATIONAL NEW DRUGS
- Physiologically‐based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment
- (2021) Mo'tasem M. Alsmadi et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements
- (2021) J. Delgado et al. ESMO Open
- Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens
- (2021) Jeffry Adiwidjaja et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making
- (2021) Nassim Djebli et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)
- (2021) Georgina Meneses-Lorente et al. INVESTIGATIONAL NEW DRUGS
- Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical Recommendations
- (2021) Jingjing Yu et al. DRUG METABOLISM AND DISPOSITION
- Clinical Biomarkers for Early Identification of Patients with Intracranial Metastatic Disease
- (2021) Karolina Gaebe et al. Cancers
- Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer
- (2021) N. Coleman et al. ESMO Open
- Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib
- (2020) Neil Parrott et al. AAPS Journal
- Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib
- (2020) Clare CHUI LING Sun et al. BLOOD
- Physiologically‐Based Pharmacokinetic Modeling Characterizes the CYP3A‐Mediated Drug‐Drug Interaction Between Fluconazole and Sildenafil in Infants
- (2020) Sara N. Salerno et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma
- (2020) Lisa Mayr et al. Journal of Personalized Medicine
- Entrectinib: First Global Approval
- (2019) Zaina T. Al-Salama et al. DRUGS
- Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice
- (2019) Jim H. Hughes et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Binding Kinetics Survey of the Drugged Kinome
- (2018) Victoria Georgi et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450
- (2017) Alex McCormick et al. XENOBIOTICA
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
- (2016) Maria Menichincheri et al. JOURNAL OF MEDICINAL CHEMISTRY
- Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling
- (2013) Zoe E. Barter et al. CLINICAL PHARMACOKINETICS
- Translational Pharmacokinetic-Pharmacodynamic Modeling from Nonclinical to Clinical Development: A Case Study of Anticancer Drug, Crizotinib
- (2012) Shinji Yamazaki AAPS Journal
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started